Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjƶgren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

ACR Expresses Concerns with MedPAC’s Drug Pricing Recommendations

From the College  |  Issue: June 2023  |  May 9, 2023

In April, the Medicare Payment Advisory Committee (MedPAC) voted to recommend a change in the add-on payment for Part B drugs in their next report to Congress.

Currently, the add-on payment is the average sales price of the drug plus 6%. The new policy recommendations would alter payment to maintain the 6% add-on payment for low-cost drugs, reduce the add-on payment for mid- to higher-cost drugs, and place a cap on the add-on payment for the costliest drugs.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The ACR sent a letter to MedPAC expressing concerns with these recommendations and highlighting the significant impacts these policies would have on rheumatologists. Of note, MedPAC recommendations are not binding; however, they do indicate future discussions on add-on payments. 

Share: 

Filed under:Legislation & Advocacy Tagged with:ACR advocacydrug pricingMedicare Part B drugs

Related Articles

    At the Table: ACR Meets with MedPAC

    May 4, 2018

    The Medicare Payment Advisory Commission (MedPAC) makes recommendations to Congress on Medicare policy including physician payments and patient access issues. These recommendations can directly impact rheumatology care coverage and rheumatologist reimbursement. Representatives of the ACR and partners recently met with new MedPAC Executive Director James E. Mathews, PhD, to discuss appropriate recognition of rheumatology care…

    Rheumatologists React to Looming Medicare Payment Reductions

    November 1, 2011

    MedPAC recommends deep cuts to physician payments

    Medicare Switch to ASP Pricing Reduces Part B Spending

    April 1, 2007

    The Medicare Payment Advisory Commission (MedPAC) reported to Congress in January that Medicare’s switch to a payment method known as ASP, or Average Sale Price, has reduced spending on drugs in the Medicare Part B program. This system reflects actual market spending, rather than wholesale prices.

    The ACR Recommends Inflation-Based Medicare Payment Updates

    March 17, 2023

    In a letter to Congress, the ACR, AMA and other groups urge legislation that would provide annual inflation-based Medicare payment updates based on the full Medicare Economic Index.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences